Drug prices: overcharging claims of ₹8,447 crore remain unpaid, Pg7

Key Highlights:

• The Centre informed the Supreme Court about capping trade margins at 30% for non-scheduled anti-cancer medicines.
• The Supreme Court questioned the government on extending similar price restrictions to other medicines and medical products.
• The National Pharmaceutical Pricing Authority (NPPA) has demanded ₹10,029.8 crore for overcharging violations since 1979, with ₹8,447.4 crore remaining unpaid as of March 31, 2026.
• The outstanding amount represents about 84% of the total demanded, with over ₹5,800 crore tied up in litigation.
• Medicine expenditure constitutes a significant portion of household hospitalisation costs, averaging nearly one-fifth in rural areas and one-seventh in urban areas.

Medicine Price Controls.jpg

Detailed Insights:

• The Supreme Court's intervention highlights concerns over steep price differences between supply costs and patient charges for medicines.
• High trade margins, while not always illegal, contribute to increased costs for patients, prompting calls for broader regulatory measures.
• The Drugs (Prices Control) Orders (DPCO) govern medicine pricing in India, and violations can lead to penalties.
• The NPPA, established in 1997, acts as the government's drug-price regulator, pursuing cases of overcharging by pharmaceutical companies.
• Despite the NPPA's efforts, a substantial portion of overcharging claims remains outstanding, indicating challenges in enforcement and recovery.
• There is currently no direct mechanism to compensate consumers for overcharged amounts, though the NPPA accepts consumer complaints.
• The large number of outstanding cases, particularly those in litigation, underscores the complexities in regulating the pharmaceutical market.

Key Concepts Involved:

• Drugs (Prices Control) Orders (DPCO): Legal framework in India that empowers the government to control the prices of essential drugs.
• National Pharmaceutical Pricing Authority (NPPA): A government regulatory body responsible for fixing and revising the prices of controlled bulk drugs and formulations.
• Trade Margins: The difference between the price at which a manufacturer sells a product to a distributor/retailer and the price at which the product is sold to the end consumer.